Clinical Trials Logo

Tumor Angiogenesis clinical trials

View clinical trials related to Tumor Angiogenesis.

Filter by:
  • None
  • Page 1

NCT ID: NCT02161978 Completed - Solid Tumor Clinical Trials

Vascular Dysfunction and Antiangiogenic Therapy

DYVA-AAGG
Start date: February 9, 2012
Phase:
Study type: Observational

project is a pilot prospective, longitudinal, before-after, open label multicentric study.

NCT ID: NCT01503697 Not yet recruiting - Breast Cancer Clinical Trials

The Role of the Novel 99mTc-NC100692 Tracer in Patients at High Risk or Known Breast Cancer

Start date: January 2012
Phase: N/A
Study type: Observational

Technetium-99m NC100692 Injection is under development as a diagnostic radiopharmaceutical for targeting angiogenesis associated with diseases such as primary and metastatic cancer, and for targeting active fibrosis in cardiac diseases such as developing heart failure and developing hypertrophic cardiomyopathy. A principle goal of imaging is identification of disease processes early in their development, at times prior to symptoms. In cancer, angiogenesis is essential for a tumour to exceed approximately 1-2 mm3 in size.As markers of angiogenesis are often expressed early in the growth of a tumour it is postulated that imaging of angiogenesis can assist in early diagnosis of cancer, relapse or spread, and monitoring response to therapy. Technetium-99m NC100692 Injection will be tested on 3 populations of pts: 1.30 patients at high risk For breast cancer 2.30 patients with breast cancer 3.15 patients with locally advanced breast cancer undergoing treatment.

NCT ID: NCT00473408 Terminated - Clinical trials for Glioblastoma Multiforme

The Effect of Radiotherapy and Temozolomide on the Tumor Vasculature and Stem Cells in Human High-grade Astrocytomas

Gliomstudien
Start date: March 2007
Phase: N/A
Study type: Observational

The purpose of the current trial is to explore whether the standard treatment with radiotherapy and temozolomide affect the tumor vasculature in patients with high-grade astrocytomas. If vascular effects are identified, future clinical trials can be proposed wherein anti-angiogenic agents are added to increase patient survival.